Business
RenovoRx Reports Second Quarter 2023 Financial Results and Operational Highlights
Presented positive Phase III TIGeR-PaC interim study results observing 8-month delay in cancer progression, concordant with 6-month overall survival benefit
About this update from Renovorx, Inc.
[{"type":"text","content":"\nPresented positive Phase III TIGeR-PaC interim study results observing 8-month delay in cancer progression, concordant with 6-month overall survival benefit and 65% reduction in adverse effects over standard of care.\n\n\nAnnounced collaboration with Imugene to explore delivery of oncolytic virus therapy using proprietary Trans-Arterial Micro-Perfusion (TAMP™) platform, expanding use from targeting locally advanced disease to treating metastatic disease.\n\n\n LOS ALTOS, Calif.--(BUSINESS WIRE)--\nRenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced financial results for the second quarter ended June 30, 2023.\n\n\n“We made strong progress this quarter and have continued momentum in our commitment to transform the lives of patients by delivering innovative solutions to change the current paradigm of cancer care,” said Shaun Bagai, CEO of RenovoRx. “This quarter marked significant milestones including positive interim data presented from our pivotal Phase III TIGeR-PaC study, a strategic collaboration to potentially utilize immunotherapy to expand our platform to help metastatic patients, and key additions to our leadership team, Board of Directors and Scientific Advisory Board. We are also excited for the upcoming year, when we expect our secondary interim analysis data readout.”\n\n\nKey Business Highlights:\n\n\n\nPresented positive Phase III data demonstrating RenovoGem delays cancer progression by 8-months, while providing a 6-month overall survival benefit and 65% reduction in adverse effects over standard of care in locally advanced pancreatic cancer patients, at 2023 ESMO World Congress in Gastrointestinal Cancer and American Association for Cancer Research Annual Meeting.\n\n\n\nInitiated patient enrollment at the University of Texas Southwestern Medical Center for pivotal Phase III TIGeR-PaC clinical trial.\n\n\n\nLaunched collaboration with Imugene Ltd (ASX: IMU) to explore a better way to deliver oncolytic immunotherapy in difficult to access to tumors, such as metastatic pancreatic cancer, using RenovoRx’s proprietary TAMP therapy platform. This collaboration potentially expands the market for the TAMP platform beyond locally advanced to metastatic pancreatic cancer.\n\n\n\nAppointed Margaret A. Tempero, M....